Tryngolza's FDA Approval and Innovation in Patient Convenience

Tryngolza, an antisense oligonucleotide (ASO) therapy targeting APOC-III developed by Ionis Pharmaceuticals (IONS), received FDA approval on June 24, 2026, for the treatment of severe hypertriglyceridemia (sHTG) in adults, with the indication to reduce triglycerides and decrease the risk of acute pancreatitis. This is the second approval, following the approval for familial chylomicronemia syndrome (FCS), a rare disease, in December 2024, and represents an expansion of the indication. In particular, the autoinjector formulation introduced with this approval allows patients to self-administer 50mg or 80mg once a month, significantly reducing the burden of hospital visits. This convenient formulation change is expected to greatly improve compliance among patients with chronic diseases and maximize long-term treatment outcomes.

Proven Efficacy Through Large-Scale Phase 3 Clinical Trials

This FDA indication expansion is based on the results of the CORE and CORE2 global Phase 3 clinical trials, which involved more than 1,000 patients with severe hypertriglyceridemia (sHTG). The researchers confirmed that in the patient group receiving Tryngolza monthly, there was a statistically significant reduction in triglycerides of up to 72% compared to the placebo group at 6 months, and this effect was maintained for 12 months. Most notably, the incidence of acute pancreatitis was reduced by as much as 85% in the treatment group compared to the placebo group. This fundamentally reduces the risk of life-threatening pancreatitis, which traditional triglyceride-lowering therapies have not been able to address, establishing Tryngolza's unique value in clinical practice.

Excellent Safety Profile and REMS Waiver Decision

As a chronic disease treatment that requires long-term use, the safety and tolerability of Tryngolza are key to its market success. The most common side effects observed during clinical trials were mild injection site reactions, and there were no cases of severe thrombocytopenia or hepatotoxicity, which were common problems with first-generation ASO therapies. Recognizing this safety, the FDA decided to approve the drug without requiring a separate Risk Evaluation and Mitigation Strategy (REMS). This significantly lowers the barrier to prescription for healthcare professionals and will undoubtedly be a strong competitive advantage in allowing rapid penetration into the market of severe hypertriglyceridemia (sHTG) patients, estimated at over 3 million in the United States.

Accelerating Global Commercialization Through Partnerships

To maximize the commercial value of Tryngolza, Ionis has formed strategic alliances with multinational pharmaceutical companies and distributors. Ionis retains exclusive rights to the U.S. market and maximizes profits, while licensing the rights for other global regions, including Europe and Asia, to Swedish Orphan Biovitrum (Sobi). Under the terms of the agreement, Ionis will receive upfront payments and milestone payments for development and commercialization, and will receive tiered royalties of up to the mid-20% range on future net sales. This strategy is expected to maximize global sales through the partner's distribution network and minimize the company's commercialization costs, paving the way for Tryngolza's global blockbuster success.